Centene Corporation reported fourth‑quarter and full‑year 2025 results, posting $49.73 billion in revenue for the quarter and $194.78 billion for the year, a 21.9% and 20.0% increase from 2024. GAAP diluted earnings per share fell to a loss of $13.53, largely driven by a $6.7 billion goodwill impairment recorded in the third quarter and other one‑time charges. Adjusted diluted EPS, which removes those non‑recurring items, rose to $2.08, beating the consensus estimate of $2.01.
Membership grew to 12.52 million in Medicaid, 5.54 million in the Marketplace, and 1.00 million in Medicare as of December 31 2025. Medicare revenue surged 75% year‑over‑year in the quarter, reflecting the impact of the Inflation Reduction Act on Part D contracts and higher utilization of high‑cost drugs. The Marketplace segment continued to expand membership, offsetting a modest decline in Medicaid enrollment, and contributed to the overall revenue growth.
The Health Benefits Ratio climbed to 91.9% for the year, up from 88.3% in 2024, as medical costs rose across behavioral health, home health, and specialty pharmaceuticals. SG&A expense remained stable at 7.4% of revenue, indicating disciplined cost management. Adjusted operating cash flow for the quarter reached $437 million, and the company maintained a strong liquidity position with $38.8 billion in cash and investments, providing a cushion for ongoing margin improvement initiatives.
Chief Executive Officer Sarah M. London said the company had “restored Marketplace profitability and stabilized the trajectory of our Medicaid business” through decisive actions taken in the second half of 2025. She emphasized that the firm is positioned to deliver meaningful margin improvement and renewed adjusted diluted EPS growth in 2026, underscoring confidence in the company’s ability to navigate rising medical costs and regulatory changes.
For 2026, Centene guided for adjusted diluted EPS greater than $3.00, surpassing the consensus estimate of $2.99. Revenue guidance for the year was set between $186.5 billion and $190.5 billion, slightly below the Street estimate of $192.7 billion, reflecting a cautious outlook amid ongoing headwinds. The guidance signals management’s belief that cost‑control measures and a favorable mix of high‑margin Medicare Advantage plans will drive earnings growth.
Investors reacted negatively to the results, citing the GAAP loss, the rising HBR, and the lower revenue guidance as concerns that outweigh the earnings beat. The market’s response highlights the importance of underlying profitability metrics and the impact of one‑time impairments on investor sentiment.
Additional context includes the divestiture of the remaining Magellan Health businesses, which generated a $513 million impairment charge, and the broader impact of the Inflation Reduction Act on Medicare Part D contracts. These events underscore Centene’s strategic focus on core government‑sponsored plans and its efforts to streamline operations and improve financial performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.